JP2020516309A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020516309A5 JP2020516309A5 JP2020503365A JP2020503365A JP2020516309A5 JP 2020516309 A5 JP2020516309 A5 JP 2020516309A5 JP 2020503365 A JP2020503365 A JP 2020503365A JP 2020503365 A JP2020503365 A JP 2020503365A JP 2020516309 A5 JP2020516309 A5 JP 2020516309A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence described
- cdr2
- antibody
- cdr1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims description 116
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims description 100
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 claims description 100
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims description 100
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 claims description 100
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 claims description 47
- 239000000427 antigen Substances 0.000 claims description 28
- 102000036639 antigens Human genes 0.000 claims description 28
- 108091007433 antigens Proteins 0.000 claims description 28
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 claims description 24
- 102000048426 human CD37 Human genes 0.000 claims description 23
- 230000035772 mutation Effects 0.000 claims description 22
- 210000004027 cell Anatomy 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 15
- 238000006467 substitution reaction Methods 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 229940124597 therapeutic agent Drugs 0.000 claims description 10
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 8
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 8
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 8
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 8
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 8
- 201000003444 follicular lymphoma Diseases 0.000 claims description 8
- 150000001413 amino acids Chemical class 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 6
- 230000003993 interaction Effects 0.000 claims description 6
- 150000007523 nucleic acids Chemical class 0.000 claims description 6
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 5
- 102000039446 nucleic acids Human genes 0.000 claims description 5
- 108020004707 nucleic acids Proteins 0.000 claims description 5
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 4
- 208000023275 Autoimmune disease Diseases 0.000 claims description 4
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 4
- 108010006654 Bleomycin Proteins 0.000 claims description 4
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims description 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 4
- 206010020751 Hypersensitivity Diseases 0.000 claims description 4
- 241000282567 Macaca fascicularis Species 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 206010052779 Transplant rejections Diseases 0.000 claims description 4
- 230000007815 allergy Effects 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 229960001561 bleomycin Drugs 0.000 claims description 4
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 4
- 229960005243 carmustine Drugs 0.000 claims description 4
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims description 4
- 229960004630 chlorambucil Drugs 0.000 claims description 4
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 4
- 229960004316 cisplatin Drugs 0.000 claims description 4
- 229960004397 cyclophosphamide Drugs 0.000 claims description 4
- 229960004679 doxorubicin Drugs 0.000 claims description 4
- 239000013604 expression vector Substances 0.000 claims description 4
- 229960000390 fludarabine Drugs 0.000 claims description 4
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 229960002450 ofatumumab Drugs 0.000 claims description 4
- 229960004641 rituximab Drugs 0.000 claims description 4
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 4
- 229960004528 vincristine Drugs 0.000 claims description 4
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 4
- 208000037979 autoimmune inflammatory disease Diseases 0.000 claims description 3
- 101100495232 Homo sapiens MS4A1 gene Proteins 0.000 claims description 2
- 108060003951 Immunoglobulin Proteins 0.000 claims description 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000012636 effector Substances 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 2
- 102000018358 immunoglobulin Human genes 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 230000000813 microbial effect Effects 0.000 claims description 2
- 239000004175 ponceau 4R Substances 0.000 claims description 2
- 210000001236 prokaryotic cell Anatomy 0.000 claims description 2
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 claims 1
- 229960002707 bendamustine Drugs 0.000 claims 1
- 230000036210 malignancy Effects 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 7
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 description 3
- -1 bendamstin Chemical compound 0.000 description 3
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 description 3
- 229960001507 ibrutinib Drugs 0.000 description 3
- 241000282412 Homo Species 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023130372A JP7680501B2 (ja) | 2017-03-31 | 2023-08-09 | 二重特異性抗ｃｄ３７抗体、モノクローナル抗ｃｄ３７抗体、およびそれらの使用方法 |
| JP2025078106A JP2025121994A (ja) | 2017-03-31 | 2025-05-08 | 二重特異性抗ｃｄ３７抗体、モノクローナル抗ｃｄ３７抗体、およびそれらの使用方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762479712P | 2017-03-31 | 2017-03-31 | |
| US62/479,712 | 2017-03-31 | ||
| EP2018057836 | 2018-03-27 | ||
| EPPCT/EP2018/057836 | 2018-03-27 | ||
| PCT/EP2018/058479 WO2018178396A1 (en) | 2017-03-31 | 2018-04-03 | Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023130372A Division JP7680501B2 (ja) | 2017-03-31 | 2023-08-09 | 二重特異性抗ｃｄ３７抗体、モノクローナル抗ｃｄ３７抗体、およびそれらの使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020516309A JP2020516309A (ja) | 2020-06-11 |
| JP2020516309A5 true JP2020516309A5 (https=) | 2021-05-13 |
| JP7330942B2 JP7330942B2 (ja) | 2023-08-22 |
Family
ID=62044657
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020503365A Active JP7330942B2 (ja) | 2017-03-31 | 2018-04-03 | 二重特異性抗ｃｄ３７抗体、モノクローナル抗ｃｄ３７抗体、およびそれらの使用方法 |
| JP2023130372A Active JP7680501B2 (ja) | 2017-03-31 | 2023-08-09 | 二重特異性抗ｃｄ３７抗体、モノクローナル抗ｃｄ３７抗体、およびそれらの使用方法 |
| JP2025078106A Pending JP2025121994A (ja) | 2017-03-31 | 2025-05-08 | 二重特異性抗ｃｄ３７抗体、モノクローナル抗ｃｄ３７抗体、およびそれらの使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023130372A Active JP7680501B2 (ja) | 2017-03-31 | 2023-08-09 | 二重特異性抗ｃｄ３７抗体、モノクローナル抗ｃｄ３７抗体、およびそれらの使用方法 |
| JP2025078106A Pending JP2025121994A (ja) | 2017-03-31 | 2025-05-08 | 二重特異性抗ｃｄ３７抗体、モノクローナル抗ｃｄ３７抗体、およびそれらの使用方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (7) | US20200270359A1 (https=) |
| EP (1) | EP3601354A1 (https=) |
| JP (3) | JP7330942B2 (https=) |
| KR (1) | KR102706161B1 (https=) |
| CN (2) | CN119285787A (https=) |
| AU (2) | AU2018242227B2 (https=) |
| BR (1) | BR112019020219A2 (https=) |
| CA (1) | CA3057907A1 (https=) |
| IL (1) | IL269645B2 (https=) |
| MX (2) | MX2019011520A (https=) |
| SG (1) | SG11201908772TA (https=) |
| UA (1) | UA127586C2 (https=) |
| WO (1) | WO2018178396A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA117901C2 (uk) * | 2011-07-06 | 2018-10-25 | Ґенмаб Б.В. | Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування |
| JP7330942B2 (ja) | 2017-03-31 | 2023-08-22 | ジェンマブ ホールディング ビー．ブイ． | 二重特異性抗ｃｄ３７抗体、モノクローナル抗ｃｄ３７抗体、およびそれらの使用方法 |
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| MX2020011552A (es) | 2018-05-03 | 2020-11-24 | Genmab Bv | Combinaciones de variantes de anticuerpos y usos de las mismas. |
| WO2019243636A1 (en) * | 2018-06-22 | 2019-12-26 | Genmab Holding B.V. | Anti-cd37 antibodies and anti-cd20 antibodies, compositions and methods of use thereof |
| EP3860715A1 (en) * | 2018-10-04 | 2021-08-11 | Genmab Holding B.V. | Pharmaceutical compositions comprising bispecific anti-cd37 antibodies |
| CN113271965B (zh) * | 2019-01-11 | 2023-11-03 | 湖南远泰生物技术有限公司 | Cd37抗体和cd37-car-t细胞 |
| WO2020160156A2 (en) | 2019-01-30 | 2020-08-06 | Immutics, Inc. | Anti-gal3 antibodies and uses thereof |
| EP4157338A4 (en) | 2020-05-26 | 2024-11-13 | TrueBinding, Inc. | METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING |
| CN113504371B (zh) * | 2021-07-09 | 2024-06-14 | 博以新(杭州)生物技术有限公司 | 基于环糊精包合的免分离化学发光免疫分析的方法 |
| JP7437558B1 (ja) | 2023-07-20 | 2024-02-22 | 株式会社ファーマフーズ | 情報処理装置、情報処理方法、およびプログラム |
| AU2024362226A1 (en) | 2023-10-18 | 2026-03-05 | Debiopharm International S.A. | Drug combination comprising anti-cd37 antibody maytansine conjugate and bcl2 inhibitor or pi3k inhibitor |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| US6077835A (en) | 1994-03-23 | 2000-06-20 | Case Western Reserve University | Delivery of compacted nucleic acid to cells |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| KR970029803A (ko) | 1995-11-03 | 1997-06-26 | 김광호 | 반도체 메모리장치의 프리차지 회로 |
| ATE299938T1 (de) | 1997-05-02 | 2005-08-15 | Genentech Inc | Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen |
| WO2000046147A2 (en) | 1999-02-03 | 2000-08-10 | Biosante Pharmaceuticals, Inc. | Therapeutic calcium phosphate particles and methods of manufacture and use |
| US6281005B1 (en) | 1999-05-14 | 2001-08-28 | Copernicus Therapeutics, Inc. | Automated nucleic acid compaction device |
| DE10043437A1 (de) | 2000-09-04 | 2002-03-28 | Horst Lindhofer | Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites |
| US7829084B2 (en) * | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| US20030103971A1 (en) | 2001-11-09 | 2003-06-05 | Kandasamy Hariharan | Immunoregulatory antibodies and uses thereof |
| US20100081792A1 (en) | 2001-06-28 | 2010-04-01 | Smithkline Beecham Corporation | Ligand |
| JP2006502091A (ja) | 2002-03-01 | 2006-01-19 | イミューノメディクス、インコーポレイテッド | クリアランス速度を高めるための二重特異性抗体点変異 |
| DK2314629T4 (da) | 2002-07-18 | 2023-02-06 | Merus Nv | Rekombinant produktion af blandinger af antistoffer |
| BRPI0315295C1 (pt) | 2002-10-17 | 2021-05-25 | Genmab As | anticorpo monoclonal humano isolado, célula hospedeira procariótica, composição farmacêutica, molécula biespecífica, usos de um anticorpo, métodos in vitro de detectar a presença de antígeno de cd20 ou uma célula que expressa cd20 em uma amostra, kit, e, vetor de expressão |
| KR20060041205A (ko) | 2003-07-01 | 2006-05-11 | 이뮤노메딕스, 인코오포레이티드 | 양특이성 항체들의 다가 담체들 |
| US7850962B2 (en) | 2004-04-20 | 2010-12-14 | Genmab A/S | Human monoclonal antibodies against CD20 |
| US7741568B2 (en) | 2005-01-13 | 2010-06-22 | The Wiremold Company | Downward facing receptacle assembly for cable raceway |
| AU2006232287B2 (en) | 2005-03-31 | 2011-10-06 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
| RU2423381C2 (ru) * | 2005-07-25 | 2011-07-10 | Трабьон Фармасьютикалз, Инк. | Снижение количества в-клеток с использованием cd37-специфических и cd20-специфических связывающих молекул |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| CA2631184A1 (en) | 2005-11-28 | 2007-05-31 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
| CA2646508A1 (en) | 2006-03-17 | 2007-09-27 | Biogen Idec Ma Inc. | Stabilized polypeptide compositions |
| PT1999154E (pt) | 2006-03-24 | 2013-01-24 | Merck Patent Gmbh | Domínios proteicos heterodiméricos modificados |
| NZ573646A (en) | 2006-06-12 | 2012-04-27 | Wyeth Llc | Single-chain multivalent binding proteins with effector function |
| AT503902B1 (de) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von immunglobulinen |
| ES2593484T3 (es) | 2007-03-29 | 2016-12-09 | Genmab A/S | Anticuerpos biespecíficos y métodos de producción de los mismos |
| EP2158221B1 (en) | 2007-06-21 | 2018-08-29 | MacroGenics, Inc. | Covalent diabodies and uses thereof |
| PE20140196A1 (es) | 2007-08-09 | 2014-03-19 | Boehringer Ingelheim Int | Anticuerpos anti-cd37 |
| EP2535349A1 (en) | 2007-09-26 | 2012-12-19 | UCB Pharma S.A. | Dual specificity antibody fusions |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| JP6157046B2 (ja) | 2008-01-07 | 2017-07-05 | アムジェン インコーポレイテッド | 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法 |
| RU2531754C2 (ru) | 2008-04-11 | 2014-10-27 | ЭМЕРДЖЕНТ ПРОДАКТ ДИВЕЛОПМЕНТ СИЭТЛ,ЭлЭлСи,US | Связывающееся с cd37 иммунотерапевтическое средство и его комбинация с бифункциональным химиотерапевтическим средством |
| WO2010015792A1 (en) | 2008-08-06 | 2010-02-11 | Argenta Discovery Limited | Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors |
| JP5397668B2 (ja) | 2008-09-02 | 2014-01-22 | ソニー株式会社 | 記憶素子および記憶装置 |
| DK2786762T3 (da) | 2008-12-19 | 2019-05-06 | Macrogenics Inc | Kovalente diabodies og anvendelser deraf |
| WO2010111625A1 (en) | 2009-03-27 | 2010-09-30 | Zymogenetics, Inc. | Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination |
| WO2010129304A2 (en) | 2009-04-27 | 2010-11-11 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| KR101224468B1 (ko) | 2009-05-20 | 2013-01-23 | 주식회사 파멥신 | 신규한 형태의 이중표적항체 및 그 용도 |
| MY192182A (en) | 2009-06-26 | 2022-08-04 | Regeneron Pharma | Readily isolated bispecific antibodies with native immunoglobulin format |
| WO2011028952A1 (en) | 2009-09-02 | 2011-03-10 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
| CN102770456B (zh) | 2009-12-04 | 2018-04-06 | 弗·哈夫曼-拉罗切有限公司 | 多特异性抗体、抗体类似物、组合物和方法 |
| SG10201501803YA (en) | 2010-03-12 | 2015-05-28 | Immunogen Inc | Cd37-binding molecules and immunoconjugates thereof |
| AR080794A1 (es) | 2010-03-26 | 2012-05-09 | Hoffmann La Roche | Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2 |
| HRP20241208T1 (hr) | 2010-04-20 | 2024-11-22 | Genmab A/S | Heterodimerni proteini koji sadrže fc fragment protutijela i postupci za njihovu proizvodnju |
| US9527926B2 (en) | 2010-05-14 | 2016-12-27 | Rinat Neuroscience Corp. | Heterodimeric proteins and methods for producing and purifying them |
| US20120189618A1 (en) | 2010-07-16 | 2012-07-26 | Boehringer Ingelheim International Gmbh | Superior efficacy of cd37 antibodies in cll blood samples |
| CN103261220B (zh) | 2010-08-16 | 2016-06-15 | 诺夫免疫股份有限公司 | 用于生成多特异性和多价抗体的方法 |
| CN103068847B (zh) | 2010-08-24 | 2019-05-07 | 罗切格利卡特公司 | 可活化的双特异性抗体 |
| CN103068846B9 (zh) | 2010-08-24 | 2016-09-28 | 弗·哈夫曼-拉罗切有限公司 | 包含二硫键稳定性Fv片段的双特异性抗体 |
| ES2758994T3 (es) | 2010-11-05 | 2020-05-07 | Zymeworks Inc | Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc |
| AU2012236210B2 (en) | 2011-04-01 | 2016-02-04 | Immunogen, Inc. | CD37-binding molecules and immunoconjugates thereof |
| CN103796678B (zh) | 2011-04-20 | 2018-02-27 | 健玛保 | 针对her2的双特异性抗体 |
| CN102250246A (zh) | 2011-06-10 | 2011-11-23 | 常州亚当生物技术有限公司 | 抗VEGF/PDGFRβ双特异性抗体及其应用 |
| UA117901C2 (uk) | 2011-07-06 | 2018-10-25 | Ґенмаб Б.В. | Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування |
| SG11201401422VA (en) | 2011-10-27 | 2014-09-26 | Genmab As | Production of heterodimeric proteins |
| RS60499B1 (sr) | 2011-12-20 | 2020-08-31 | Medimmune Llc | Modifikovani polipeptidi za bispecifične skelete antitela |
| US9248181B2 (en) | 2012-04-20 | 2016-02-02 | Merus B.V. | Methods and means for the production of Ig-like molecules |
| JP2015517511A (ja) * | 2012-05-16 | 2015-06-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｄ３７抗体とｉｃｅ（イフォスファミド、カルボプラチン、エトポシド）の併用 |
| CN104736174B (zh) * | 2012-07-06 | 2019-06-14 | 根马布私人有限公司 | 具有三重突变的二聚体蛋白质 |
| DK2924052T3 (da) | 2012-11-21 | 2019-09-30 | Pharmabcine Inc | Dual-target-antistof målrettet mod vegfr-2 og dll4, og farmaceutisk sammensætning omfattende samme |
| KR20200024345A (ko) * | 2013-01-10 | 2020-03-06 | 젠맵 비. 브이 | 인간 IgG1 Fc 영역 변이체 및 그의 용도 |
| WO2015017552A1 (en) * | 2013-08-01 | 2015-02-05 | Agensys, Inc. | Antibody drug conjugates (adc) that bind to cd37 proteins |
| WO2017053423A1 (en) | 2015-09-21 | 2017-03-30 | Erasmus University Medical Center | Anti-cd47 antibodies and methods of use |
| US20190276549A1 (en) | 2016-11-01 | 2019-09-12 | Genmab B.V. | Polypeptide variants and uses thereof |
| US20230399414A1 (en) | 2017-03-31 | 2023-12-14 | Genmab Holding B.V, | Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereof |
| JP7330942B2 (ja) | 2017-03-31 | 2023-08-22 | ジェンマブ ホールディング ビー．ブイ． | 二重特異性抗ｃｄ３７抗体、モノクローナル抗ｃｄ３７抗体、およびそれらの使用方法 |
| WO2019243636A1 (en) | 2018-06-22 | 2019-12-26 | Genmab Holding B.V. | Anti-cd37 antibodies and anti-cd20 antibodies, compositions and methods of use thereof |
-
2018
- 2018-04-03 JP JP2020503365A patent/JP7330942B2/ja active Active
- 2018-04-03 WO PCT/EP2018/058479 patent/WO2018178396A1/en not_active Ceased
- 2018-04-03 IL IL269645A patent/IL269645B2/en unknown
- 2018-04-03 UA UAA201910706A patent/UA127586C2/uk unknown
- 2018-04-03 CN CN202411136586.4A patent/CN119285787A/zh active Pending
- 2018-04-03 US US16/498,104 patent/US20200270359A1/en not_active Abandoned
- 2018-04-03 CA CA3057907A patent/CA3057907A1/en active Pending
- 2018-04-03 AU AU2018242227A patent/AU2018242227B2/en active Active
- 2018-04-03 SG SG11201908772T patent/SG11201908772TA/en unknown
- 2018-04-03 BR BR112019020219-6A patent/BR112019020219A2/pt unknown
- 2018-04-03 CN CN201880032561.6A patent/CN110914301B/zh active Active
- 2018-04-03 EP EP18719454.3A patent/EP3601354A1/en active Pending
- 2018-04-03 KR KR1020197032125A patent/KR102706161B1/ko active Active
- 2018-04-03 MX MX2019011520A patent/MX2019011520A/es unknown
-
2019
- 2019-09-26 MX MX2023011121A patent/MX2023011121A/es unknown
-
2020
- 2020-05-11 US US16/872,140 patent/US11512137B2/en active Active
- 2020-10-08 US US17/066,190 patent/US11034772B2/en active Active
-
2021
- 2021-07-22 US US17/382,758 patent/US11396553B2/en active Active
- 2021-11-23 US US17/534,029 patent/US12448459B2/en active Active
-
2022
- 2022-10-27 US US17/975,362 patent/US20240117064A1/en not_active Abandoned
-
2023
- 2023-08-09 JP JP2023130372A patent/JP7680501B2/ja active Active
- 2023-10-27 US US17/975,353 patent/US12577316B2/en active Active
-
2025
- 2025-05-08 JP JP2025078106A patent/JP2025121994A/ja active Pending
- 2025-06-13 AU AU2025204448A patent/AU2025204448A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020516309A5 (https=) | ||
| CN105012953B (zh) | 用cd37-特异性和cd20-特异性结合分子减少b-细胞 | |
| EP2331579B1 (en) | Monoclonal antibodies | |
| JP5723279B2 (ja) | 抗ｃｘｃｒ４抗体および癌治療のためのそれらの使用 | |
| CN102421802B (zh) | 人源化的axl抗体 | |
| JP2020501531A5 (https=) | ||
| Strohl | Structure and function of therapeutic antibodies approved by the US FDA in 2023 | |
| KR20180050321A (ko) | 분자를 표적화하기 위한 항원 결합 구조체 | |
| Marrocco et al. | Cancer immunotherapy: the dawn of antibody cocktails | |
| WO2017026497A1 (ja) | 抗体 | |
| JP2021522303A5 (https=) | ||
| JP2023547506A5 (https=) | ||
| KR20230028386A (ko) | 인간 질환의 치료를 위한 cd38 항체 | |
| JP2021528439A5 (https=) | ||
| JP2023540618A5 (https=) | ||
| TWI917473B (zh) | Bcma/taci抗原結合分子 | |
| EP4620973A1 (en) | Antibodies targeting cell surface deposited complement protein c3d and use thereof | |
| AU2016216708A1 (en) | Monoclonal antibodies | |
| CA3258963A1 (en) | POLYTHERAPY INCLUDING A SIRP ALPHA FUSION PROTEIN AND AN ANTI-CD19 ANTIBODY FOR CANCER TREATMENT | |
| AU2009288700B2 (en) | Monoclonal antibodies | |
| RU2021112351A (ru) | Фармацевтические композиции, включающие биспецифические анти-cd37 антитела | |
| HK1156499A (en) | B-cell reduction using cd37-specific and cd20-specific binding molecules |